Worth reading
43Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
45.9
% (year-on-year increase in operating profit)Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)2024年4月1日〜2024年9月30日ConsolidatedJapanese GAAPNet Sales34,756¥ millionYear on year +28.1%Progress 51.1%
Operating profit8,145¥ millionYear on year +45.9%Progress 60.3%
Ordinary income7,948¥ millionYear on year +27.3%Progress 58.0%
Net income attributable to owners of the parent5,608¥ millionYear on year +30.8%Progress 61.3%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share159.09円
Financial position at period-end
Total assets134,893¥ million
of which net assets 98,865 ¥ millionEquity ratio 73.3%vs. prior year-end +2.2pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+14,566,307
Investment-12,778,039
Financials-1,168,841
Net change+619,427
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥29,771,278 thousand
Segment revenueLife Sciences Business ¥18,668,540 thousand (YoY +10.0%), 電子材料および機能性化学品事業 ¥16,087,813 thousand (YoY +58.4%)
Segment profitLife Sciences Business ¥2,741,337 thousand (YoY -16.3%), 電子材料および機能性化学品事業 ¥6,516,552 thousand (YoY +95.7%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥68,000 million (YoY +15.3%)
Operating profit¥13,500 million (YoY +21.8%)
Ordinary income¥13,700 million (YoY +15.3%)
Net income¥9,150 million (YoY +9.7%)
Revision to Earnings ForecastNo change → No change
Annual Dividend Forecast¥66 → ¥70
Factors Behind Changes in Business Performance
新規顧客の開拓・既存顧客との関係強化・価格改定などの営業活動の強化、半導体市場の回復による超高純度コロイダルシリカの販売数量増加、価格改定や円安効果により増収増益となった。ライフサイエンス事業では、輸入価格・エネルギー価格の上昇や定期修繕による生産量減少により増収減益となった。
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Yesそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNo material changes (no newly consolidated or excluded companies, or company names, are disclosed)
Impairment loss計上なし（セグメント情報で該当事項はありません）
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥60,928 thousand, Subsidy Income ¥20,257 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥21,405 thousand
Depreciation and amortization¥3,702,681 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingYes (for institutional investors)
Issued Shares at Period-End35,511,000
Treasury Shares at Period-End253,983
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2024年4月1日〜2024年9月30日 |
| Net Sales | ¥34,756 million (YoY +28.1%) |
| Operating profit | ¥8,145 million (YoY +45.9%) |
| Ordinary income | ¥7,948 million (YoY +27.3%) |
| Profit attributable to owners of the parent | ¥5,608 million (YoY +30.8%) |
| Net income per share | 159.09円 |
| Equity ratio | End of the current fiscal period 73.3 / End of previous period 71.1 |
| Total assets | ¥134,893 million |
| Net assets | ¥98,865 million |
| Cash flows from operating activities | ¥14,566,307 thousand |
| Cash flows from investing activities | ¥-12,778,039 thousand |
| Cash flows from financing activities | ¥-1,168,841 thousand |
| Cash and cash equivalents at end of period | ¥29,771,278 thousand |
| Full-year earnings forecast | Net Sales ¥68,000 million (YoY +15.3%) / Operating profit ¥13,500 million (YoY +21.8%) / Ordinary income ¥13,700 million (YoY +15.3%) / Net income ¥9,150 million (YoY +9.7%) |
| Revision to Earnings Forecast | No change → No change |
| Annual Dividend Forecast | ¥66 → ¥70 |
| Segment revenue | Life Sciences Business ¥18,668,540 thousand (YoY +10.0%), 電子材料および機能性化学品事業 ¥16,087,813 thousand (YoY +58.4%) |
| Segment profit | Life Sciences Business ¥2,741,337 thousand (YoY -16.3%), 電子材料および機能性化学品事業 ¥6,516,552 thousand (YoY +95.7%) |
| Depreciation and amortization | ¥3,702,681 thousand |
| Impairment loss | 計上なし（セグメント情報で該当事項はありません） |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥60,928 thousand, Subsidy Income ¥20,257 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥21,405 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | No material changes (no newly consolidated or excluded companies, or company names, are disclosed) |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Yes (for institutional investors) |
| Issued Shares at Period-End | 35,511,000 |
| Treasury Shares at Period-End | 253,983 |
| Factors Behind Changes in Business Performance | 新規顧客の開拓・既存顧客との関係強化・価格改定などの営業活動の強化、半導体市場の回復による超高純度コロイダルシリカの販売数量増加、価格改定や円安効果により増収増益となった。ライフサイエンス事業では、輸入価格・エネルギー価格の上昇や定期修繕による生産量減少により増収減益となった。 |
Items this document does not state (6)
Operating MarginPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.新規顧客の開拓、既存顧客との関係強化、価格改定などの営業活動を強化したほか、原料資材の安定確保や製造活動の強化・安定化に取り組んだ。半導体市場の回復による超高純度コロイダルシリカの販売数量増加、価格改定、円安効果なども寄与した。一方、ライフサイエンス事業では輸入価格・エネルギー価格の上昇や定期修繕による生産量減少が営業利益を押し下げた。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.